Clinic Roundup

Durect Corp., of Cupertino, Calif., said top-line results from a Phase II trial showed that Eladur (Transdur-Bupivacaine), its transdermal bupivacaine pain patch, missed the primary endpoint of demonstrating a positive treatment difference over placebo for the mean change in pain intensity scores from baseline to the mean of week 11 and week 12. Complete data analysis is ongoing.